What if chemotherapy could be targeted to only attack a patient's tumor?
That's the promise of Antibody-Drug Conjugates.
In this clip from our latest Webinar, Jason Sager, MD, explains what antibody-drug conjugates are and what they mean for cancer patients.
We discuss how patients get access and what they can expect in treatment.
Many ADCs have been approved for different types of cancer and many are available in clinical trials.
Most patients are handed a treatment plan and told to begin. But what if there are better options—or steps being missed?
This free 5-day email series helps you understand the hidden opportunities that could shape your care. It covers what many patients wish they had known sooner—before key decisions were made.
You’ll get insights on:
Each short email builds on the last, helping you feel more informed and in control—right when decisions matter most.
Join hundreds of patients gaining clarity and confidence—in just 5 short emails.
